A Phase I/Ii Study Of Vorinostat, An Oral Histone Deacetylase Inhibitor, In Combination With Azacitidine In Patients With The Myelodysplastic Syndrome (Mds) And Acute Myeloid Leukemia (Aml). Initial Results Of The Phase I Trial: A New York Cancer Consortium